Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Receives Authorization To Proceed From Fda And Doses First Subject With Bhv-3500, Third-generation, Small Molecule Cgrp-receptor Antagonist
LPNEWS

Biohaven Receives Authorization To Proceed From Fda And Doses First Subject With Bhv-3500, Third-generation, Small Molecule Cgrp-receptor Antagonist

by prnewswire.com posted 11months ago 174 views
NEW HAVEN, Conn., Oct. 22, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that the first participant was dosed with BHV-3500, a third generation...

In this article